Skip to main content
. 2022 Nov 30;379:e073070. doi: 10.1136/bmj-2022-073070

Table 1.

Population characteristics after matching, by test result and vaccination status. Values are numbers (percentages) unless stated otherwise

Characteristic Overall (n=278 642) Test result Vaccination status
Negative (n=139 321) Positive (n=139 321) P value Unvaccinated (n=60 205) Partially vaccinated (n=37 941) Fully vaccinated (n=150 966) Boosted (n=3755) Other* (n=25 775)
Any comorbidity: 1
 No 265 422 (95.3) 132 711 (95.3) 132 711 (95.3) 56 162 (93.3) 36 040 (95.0) 145 172 (96.2) 3706 (98.7) 24 342 (94.4)
 Yes 13 220 (4.7) 6610 (4.7) 6610 (4.7) 4043 (6.7) 1901 (5.0) 5794 (3.8) 49 (1.3) 1433 (5.6)
Sex: 1
 Female 142 988 (51.3) 71 494 (51.3) 71 494 (51.3) 29 447 (48.9) 19 022 (50.1) 79 594 (52.7) 2078 (55.3) 12 847 (49.8)
 Male 135 654 (48.7) 67 827 (48.7) 67 827 (48.7) 30 758 (51.1) 18 919 (49.9) 71 372 (47.3) 1677 (44.7) 12 928 (50.2)
Type of test: 1
 RT-PCR 120 420 (43.2) 60 210 (43.2) 60 210 (43.2) 30 218 (50.2) 16 362 (43.1) 58 973 (39.1) 2637 (70.2) 12 230 (47.4)
 Antigen 158 222 (56.8) 79 111 (56.8) 79 111 (56.8) 29 987 (49.8) 21 579 (56.9) 91 993 (60.9) 1118 (29.8) 13 545 (52.6)
Mean (SD) week of diagnosis 17.4 (4.9) 17.4 (4.9) 17.4 (4.9) 1 14.3 (6.9) 17.5 (3.9) 18.7 (3.2) 22.6 (4.4) 16.5 (5.2)
Age group (years): 0.82
 3-11 145 705 (52.3) 72 822 (52.3) 72 883 (52.3) 39 390 (65.4) 23 460 (61.8) 66 831 (44.3) 277 (7.4) 15 747 (61.1)
 12-17 132 937 (47.7) 66 499 (47.7) 66 438 (47.7) 20 815 (34.6) 14 481 (38.2) 84 135 (55.7) 3478 (92.6) 10 028 (38.9)
Time since second dose of vaccine†: (n=150 966) (n=77 557) (n=73 409) <0.001
 <60 days 72 515 (48.0) 39 951 (51.5) 32 564 (44.4) - - 72 515 (48.0) - -
 ≥60 days 78 451 (52.0) 37 606 (48.5) 40 845 (55.6) - - 78 451 (52.0) - -

RT-PCR=reverse transcription polymerase chain reaction; SD=standard deviation.

*

Includes participants who were vaccinated in the two weeks before their test, those who received another vaccine, and those with inconsistent or incomplete vaccination data.

In fully vaccinated participants.